Rigel Pharmaceuticals, Inc.

Investors News & Events Contact Us
  • Home
  • Who We Are
    • Company Overview
    • Management Team
    • Board of Directors
    • Partners
  • Pipeline
    • Clinical Programs
    • IRAK1/4
    • RIPK1
    • Partnered Programs
    • Clinical Trials
    • Investigator Sponsored Research
    • Expanded Access Policy
  • Products
  • Join Our Team
    • Life at Rigel
    • Our Values
    • Benefits
    • Current Openings
  • Investors
  • News & Events
  • Contact Us

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Press Releases
    • Events & Presentations
    • Email Alerts
  • Financial Info
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • FAQ
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Analyst Coverage
  • Governance
    • Management Team
    • Board of Directors
    • Board Committees
    • Governance Documents
  • ESG
  • News & Events

  • Press Releases
  • Events & Presentations
  • Email Alerts
Jan 10, 2022 8:40am EST

Rigel Pharmaceuticals Provides Business Update

Dec 21, 2021 8:30am EST

Fostamatinib Meets Primary Endpoint in Phase 3 Trial in Japan for Treatment of Chronic Immune Thrombocytopenia

Dec 16, 2021 9:00am EST

Rigel Appoints Kamil Ali-Jackson to Board of Directors

Nov 15, 2021 8:30am EST

Rigel Sharpens Focus on Its Advanced Portfolio Opportunities

Nov 09, 2021 7:30am EST

Rigel to Participate in Two Upcoming Investor Conferences

Nov 02, 2021 4:01pm EDT

Rigel Reports Third Quarter 2021 Financial Results and Provides Business Update

Oct 26, 2021 7:30am EDT

Rigel Announces Conference Call and Webcast to Report Third Quarter 2021 Financial Results and Business Update

Sep 28, 2021 4:00pm EDT

Grifols begins commercializing TAVLESSE® in France, Italy and Spain to treat chronic immune thrombocytopenia

Sep 02, 2021 7:30am EDT

Rigel to Participate in Three Upcoming Investor Conferences

Sep 01, 2021 7:30am EDT

Data from NIH/NHLBI-Sponsored Phase 2 Trial of Fostamatinib in Hospitalized COVID-19 Patients Published in Clinical Infectious Diseases

  • Previous
  • 1…
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • …41
  • Next
RSS
  • Email Alerts
  • RSS News Feed
Terms of Use Privacy Policy Your Cookie Preferences

© 2025 Rigel Pharmaceuticals, Inc. All Rights Reserved.

TAVALISSE, TAVLESSE, REZLIDHIA, GAVRETO, RIGEL and the Rigel arc logo are registered trademarks of Rigel Pharmaceuticals, Inc.

Facebook Twitter Linkedin